TO THE EDITOR
We read with interest the article by Kaleem et al 1 reviewing 21 cases of acute lymphoblastic leukemia (ALL) with the rare chromosomal translocation, t(8;14)(q11.2;q32), and wish to inform readers of a further three cases.
The three new patients were identified through the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in Acute Lymphoblastic Leukaemia (Database), which is responsible for co-ordinating the cytogenetic results of patients submitted to the UK treatment trials for ALL. Patient 1 was entered to the current childhood trial, ALL97; patient 2 to the current adult trial, UKALLXII and patient 3 to the previous adult trial, UKALLX. Cytogenetic analysis was carried out on diagnostic bone marrow samples in the local UK cytogenetics laboratories. Slide review and fluorescence in situ hybridization (FISH) studies were carried out at the Database.
The clinical and cytogenetic findings of these three patients are summarised in Table 1 . Of the two patients whose immunophenotype was known, both had a precursor B phenotype. In all three patients WBC counts were below 20 × 10 9 /l with no CNS involvement. Organomegaly was observed at presentation in patient 1. Following two bone marrow relapses at 39 and 47 months and an unrelated donor bone marrow transplant in her third remission at 49 months, she remains alive 8 years post diagnosis. Although follow-up time is short, patients 2 and 3 remain in continuous complete remission. Patient 3 has Down's syndrome, which was described in six of the 21 previously reported cases.
All three patients showed chromosomal changes in association with t(8;14)(q11;q32). Patient 1 had a t(9;22)(q34;q11) translocation giving rise to the Philadelphia chromosome, also found in three of the previously reported cases. [1] [2] [3] Of interest in this patient was the observation that the t(9;22) was retained at both relapses but the t(8;14) 1 FISH using whole chromosome paints for chromosomes 8 and 19 (Appligene-Oncor, Illkirch, France) confirmed this to be a derived chromosome 19, der(19)t(8;19)(?;p13). The deletion of the short arm of chromosome 12, del(12p), observed in patient 3 was confirmed by FISH during the routine application of the LSI TEL/AML1 dual color probe (Vysis, Richmond, UK) to investigate the presence of the translocation, t(12;21)(p13;q22), commonly found in childhood ALL. The signal for the ETV6 gene was absent from the del(12p).
Rearrangements of the JH region of the immunoglobulin heavy chain locus (IGH) in this translocation were verified by Southern analysis in two of the previously reported cases. 4 It has been postulated that the gene involved on chromosome 8 could be IL7, but to date this has not been confirmed. We corroborate the involvement of the IGH gene in two of our three cases (2 and 3) by FISH using the LSI IGH/CCND1 dual-color probe (Vysis). This probe is designed to detect the juxtaposition of IGH sequences with cyclin D1 (CCND1) in mantle cell lymphoma with a t(11;14)(q13;q32). Since the IGH probe set contains two Spectrum green-labeled probes which hybridize to sequences 5′ and 3′ of the IGH J region breakpoint, breaks occurring within the J region can be identified by the separation of these two probes. In patients 2 and 3, three IGH signals were observed, one representing the co-localized 5′and 3′ signals on the normal chromosome 14 and second and third signals representing the separated 5′ and 3′ signals on the derived chromosomes 8 and 14, respectively ( Figure 1) . This is the first reported FISH study of the t(8;14)(q11;q32) translocation in which these findings confirm the involvement of IGH and the reciprocal nature of the translocation. These three new cases increase the number of reported cases with this translocation to 24 and strengthen the association with Down's syndrome.
Figure 1
A representative metaphase from patient 2 hybridized with the LSI IGH/CCND1 dual-color probe. The CCND1 signals on the two normal chromosomes 11 are shown in red. The IGH signal on the normal chromosome 14 is shown in green (pink arrow) and the split IGH signal is present on the derived chromosomes 8 (5′ IGH) (white arrow) and 14 (3′ IGH) (yellow arrow).
Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture

TO THE EDITOR
Chronic lymphocytic leukemia (B-CLL) is a hematologic malignancy that afflicts middle-aged and elderly individuals and is characterized by the accumulation of long-lived non-dividing CD5 + B cells in G 0 of the cell cycle.
1 Although B-CLL cells are long-lived in vivo, they undergo rapid and spontaneous apoptosis when cultured in vitro.
2 B-CLL cells express the anti-apoptotic protein bcl-2, which may promote their viability and resistance to apoptosis in vivo. 3 Bcl-2 levels decrease during in vitro culture of B-CLL cells and bcl-2 levels are inversely correlated with the susceptibility of cultured B-CLL cells to undergo spontaneous apoptosis. 4 The spontaneous apoptosis of B-CLL cells during in vitro culture provides both a challenge and opportunity to understand B-CLL cell biology. Understanding the factors that maintain B-CLL cell viability in vitro may identify factors necessary for B-CLL cell viability in vivo. Studies performed by Rosen and coworkers 5 indicated increased viability of B-CLL cells during in vitro culture in Iscove's modification of Dulbecco's medium supplemented with bovine serum albumin,
